CAR T Cells Produced in vivo to Treat Cardiac Injury
Joel G. Rurik(Karolinska Institutet), Jonathan A. Epstein(University of Pennsylvania), Ellen Puré(University of the Sciences), Steven Μ. Albelda(University of Pennsylvania), Carl H. June(University of Pennsylvania), Tyler E. Papp(Translational Therapeutics (United States)), Barbara L. Mui(Arbutus Biopharma (Canada)), Amir Yadegari(Shahid Beheshti University of Medical Sciences), István Tombácz(University of Pennsylvania), Li Li(University of Pennsylvania), Ousamah Younoss Soliman(University of Pennsylvania), Ying K. Tam(Arbutus Biopharma (Canada)), Drew Weissman(California University of Pennsylvania), Hamideh Parhiz(Translational Therapeutics (United States)), Haig Aghajanian(Therapeutics Clinical Research), Swapnil V. Shewale(University of Pennsylvania), Tōru Kimura(Josai University), Pedro O. Méndez Fernández(California Institute for Regenerative Medicine)
HAL (Le Centre pour la Communication Scientifique Directe)
February 9, 2023
Cited by 940
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Adhesion molecules and inflammatory injury
|The FASEB Journal|1994|1k